Joerg Hasford

15.0k total citations · 2 hit papers
188 papers, 7.0k citations indexed

About

Joerg Hasford is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Joerg Hasford has authored 188 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Hematology, 56 papers in Genetics and 32 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Joerg Hasford's work include Chronic Myeloid Leukemia Treatments (56 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Eosinophilic Disorders and Syndromes (25 papers). Joerg Hasford is often cited by papers focused on Chronic Myeloid Leukemia Treatments (56 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Eosinophilic Disorders and Syndromes (25 papers). Joerg Hasford collaborates with scholars based in Germany, Netherlands and United States. Joerg Hasford's co-authors include Rüdiger Hehlmann, Markus Pfirrmann, Wolfgang Hiddemann, Michael Unterhalt, Sebastian Schneeweiß, Hanneke C. Kluin‐Nelemans, Martin Dreyling, Eva Hoster, Jürgen Stausberg and Andreas Hochhaus and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Joerg Hasford

184 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Hanneke C. Kluin‐Nelemans, Joerg Hasford et al. profile →
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group

1998 518 citations Joerg Hasford, Markus Pfirrmann et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by Joerg Hasford

Since Specialization

Citations

This map shows the geographic impact of Joerg Hasford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joerg Hasford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joerg Hasford more than expected).

Fields of papers citing papers by Joerg Hasford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joerg Hasford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joerg Hasford. The network helps show where Joerg Hasford may publish in the future.

Co-authorship network of co-authors of Joerg Hasford

This figure shows the co-authorship network connecting the top 25 collaborators of Joerg Hasford. A scholar is included among the top collaborators of Joerg Hasford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joerg Hasford. Joerg Hasford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Four reasons why too many informed consents to clinical research are invalid: a critical analysis of current practices 2022 ·BMJ Open ·(unknown), Joerg Hasford	8
2	Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol 2021 ·BMJ Open ·Anette‐Gabriele Ziegler, (unknown), (unknown), Peter Achenbach, Reinhard Berner, Ezio Bonifacio, Kristina Casteels, Helena Elding Larsson, Melanie Gündert, Joerg Hasford, Olga Kordonouri, Markus Lundgren, Mariusz Ołtarzewski, Marcin Ł. Pękalski, Markus Pfirrmann, Matthew D. Snape, Agnieszka Szypowska, John A. Todd	21
3	Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol 2019 ·BMJ Open ·Anette‐Gabriele Ziegler, Peter Achenbach, Reinhard Berner, Kristina Casteels, Thomas Danne, Melanie Gündert, Joerg Hasford, Verena Hoffmann, Olga Kordonouri, Karin Lange, Helena Elding Larsson, Markus Lundgren, Matthew D. Snape, Agnieszka Szypowska, John A. Todd, Ezio Bonifacio	58
4	Screening for asymptomatic β-cell autoimmunity in young children 2019 ·The Lancet Child & Adolescent Health ·Anette‐G. Ziegler, Georg F. Hoffmann, Joerg Hasford, Helena Elding Larsson, Thomas Danne, Reinhard Berner, Megan A. S. Penno, (unknown), Jessica L. Dunne, Ezio Bonifacio	9
5	Medizinische Ethikkommissionen in der Bundesrepublik Deutschland: Entstehung und Einbindung in die medizinische Forschung 2019 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·(unknown), Joerg Hasford	12
6	Ethische Aspekte der klinischen Prüfung bei seltenen Erkrankungen 2017 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·Joerg Hasford, Armin Koch	5
7	A compilation of research working groups on drug utilisation across Europe 2014 ·BMC Research Notes ·Mònica Sabaté, (unknown), Elena Ballarín, (unknown), H. Petri, Joerg Hasford, (unknown), Marietta Rottenkolber, Joan Fortuny, Joan‐Ramon Laporte, Luisa Ibáñez	9
8	Stationäre Aufnahmen wegen unerwünschter Arzneimittelereignisse (UAE): Analyse der DRG-Statistik 2006 2011 ·Das Gesundheitswesen ·(unknown), Joerg Hasford, Jürgen Stausberg	7
9	Analysis of hospital admissions associated with digitalis glycosides 2007 ·Medizinische Klinik - Intensivmedizin und Notfallmedizin ·Sven Schmiedl, (unknown), Marietta Rottenkolber, Bernd Drewelow, (unknown), Marion Hippius, (unknown), Werner Siegmund, Karen May, Sara Haack, Joerg Hasford, Petra Thürmann, (unknown)	7
10	Gender aspects in chronic myeloid leukemia: long-term results from randomized studies 2005 ·Leukemia ·Ute Berger, Ole Maywald, Markus Pfirrmann, Tanja Lahaye, Andreas Hochhaus, Andreas Reiter, Joerg Hasford, H. Heimpel, D. K. Hossfeld, H-J Kolb, H. Löffler, H. Pralle, W. Queißer, Rüdiger Hehlmann, (unknown)	54
11	A Prospective Randomized Comparison of Unsedated Ultrathin Versus Standard Esophagogastroduodenoscopy in Routine Outpatient Gastroenterology Practice: Does It Work Better through the Nose? 2003 ·Endoscopy ·(unknown), (unknown), (unknown), Joerg Hasford	61
12	Adverse drug reaction monitoring – digitoxin overdosage in the elderly 2001 ·International Journal of Clinical Pharmacology and Therapeutics ·Marion Hippius, (unknown), (unknown), A Hoffmann, (unknown), Joerg Hasford	8
13	Assessing the Safety of Drugs in Pregnancy 2000 ·Drug Safety ·(unknown), Joerg Hasford	18
14	Einfluss eines optimierten Schnittstellenmanagements auf die Langzeiteffektivität der kardiologischen Rehabilitation 2000 ·DMW - Deutsche Medizinische Wochenschrift ·(unknown), (unknown), (unknown), (unknown), (unknown), Joerg Hasford	8
15	A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group breakdown → 1998 ·JNCI Journal of the National Cancer Institute ·Joerg Hasford, Markus Pfirrmann, Rüdiger Hehlmann, N. C. Allan, Michele Baccarani, Hanneke C. Kluin‐Nelemans, G. Alimena, Juan Luis Steegmann, Hassan Ansari	518
16	Analysis and validation of prognostic factors for CML 1996 ·Bone Marrow Transplantation ·Joerg Hasford, (unknown), Markus Pfirrmann, Rüdiger Hehlmann	23
17	Roferon (rIFN-α _2a ) Is More Immunogenic Than Intron A (rIFN-α _2b ) in Patients with Chronic Myelogenous Leukemia 1994 ·Journal of Interferon Research ·Peter von Wussow, R. Hehlmann, (unknown), D Jakschies, (unknown), Otto Prümmer, (unknown), Joerg Hasford, H. Heimpel, H. Deicher	24
18	Evaluating quality-of-life measures for clinical trials in Germany 1991 ·Controlled Clinical Trials ·Monika Bullinger, Joerg Hasford	53
19	Vorteile und Probleme multizentrischer Therapiestudien am Beispiel einer Studie zur Behandlung des metastasierenden Nierenzellkarzinoms mit rekombinantem Interferon-Alpha-2C 1987 ·Oncology Research and Treatment ·D. Messerer, Franz Porzsolt, Joerg Hasford, A. Neiß	7
20	Risk-benefit analyses of drugs: Fundamental considerations and requirements from the point of view of the biometrician. Problems in the assessment of the combination of trimethoprim with sulfamethoxazole 1987 ·Infection ·N. Victor, Joerg Hasford	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact